美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

美國抗疫概念

1,374.50

+9.860.72%

漲家數：15

跌家數：5

平家數：- -

市盈率：- -

高：1,380.29

開：1,364.76

低：1,358.78

收：1,364.65

資料載入中...

新冠疫苗研發波折：Vaxart 獲轉機，行業仍陷困境

生物制品圈

Ibio, Inc.盤中異動快速上漲6.19%報1.12美元

Corvus Pharmaceuticals, Inc.盤中異動早盤股價大漲5.43%報3.69美元

美國食品和藥物管理局局長稱解僱不會妨礙該局的藥物審查目標日期

BUZZ-輝瑞公司季度利潤增長，維持 2025 年業績預期

輝瑞依靠削減成本抵消收入下降的影響

輝瑞季度銷售額不及預期，COVID 治療收入下降

阿斯利康一季報：中國區收入18億美元，ADC藥物驅動新增長

21世纪经济报道

阿斯利康盤前挫2.65% 將終止針對其前列腺癌治療藥物三期臨牀試驗

美股異動丨阿斯利康盤前跌超3% 首季收入遜預期或因未支付進口稅面臨中國罰款

阿斯利康(AZN.O)CEO：美國關税對阿斯利康的影響將是短暫的。

阿斯利康 Q1：中國區收入 18 億美元，Enhertu 大賣 10.86 億美元

Insight数据库

強生4月28日成交額為9.02億美元

吉利德科學4月28日成交額為9.98億美元

Virtual Protocol生態代幣普漲，GAME 24H漲幅超50%

阿斯利康4月28日成交額為5.63億美元

敬告客戶-以下稿子現予以撤銷-特朗普吹捧Nvidia、J&J、現代、豐田在美投資

吉利德科學盤中異動股價大漲3.00%

Nanoviricides, Inc.盤中異動快速下挫7.04%報1.32美元

BUZZ-Insulet 任命新任首席執行官，預示利潤前景改善，公司股價上漲

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4568/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"美國抗疫概念","latestPrice":1374.5028,"timestamp":1746043199999,"preClose":1364.6454,"halted":0,"volume":107932090,"delay":0,"changeRate":0.007223,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":9.857422,"latestTime":"04-30 16:00:00 EDT","open":1364.7573,"high":1380.285,"low":1358.7754,"amount":5579245656.600088,"amplitude":0.015762,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1746106200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.657153,"peRate":21.867348,"turnoverRate":0.00696,"increases":15,"decrements":5,"flats":0,"marketCap":1135599575121,"floatMarketCap":1115674225455},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1380.285,"amplitude":0.015762,"preClose":1364.6454,"low":1358.7754,"pbRate":"3.657153","latestPrice":1374.5028,"volume":107932090,"delay":0,"open":1364.7573,"prevYearClose":1274.8187,"prevWeekClose":1341.1263,"prevMonthClose":1374.5028,"prevQuarterClose":1427.887,"fiveDayClose":1344.1606,"twentyDayClose":1377.6108,"sixtyDayClose":1350.7439,"secType":"PLATE","market":"US","turnoverRate":0.00696,"peRate":21.867348,"marketCap":1135599575121,"floatMarketCap":1115674225455,"timestamp":1746043199999,"nameCN":"美國抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":15,"down":5,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531134867","title":"新冠疫苗研發波折：Vaxart 獲轉機，行業仍陷困境","url":"https://stock-news.laohu8.com/highlight/detail?id=2531134867","media":"生物制品圈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531134867?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 21:56","pubTimestamp":1745935014,"startTime":"0","endTime":"0","summary":"近日，疫苗研发领域动态频出，Vaxart 公司迎来好消息，其新冠疫苗研究的暂停令被解除，研发进程得以重启。此前，HHS 在 2 月冻结了 Vaxart 的试验，这一举措使得该公司与政府签订的价值数十亿美元的口服新冠疫苗研发合同陷入僵局。其他公司受阻，研发之路艰难尽管 Vaxart 迎来转机，但其他新冠疫苗研发企业却仍在困境中挣扎。Vaxart 公司新冠疫苗研究的恢复为其带来了希望，但新冠疫苗研发行业整体仍面临监管、舆论等多方面的压力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430052357a46cac01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430052357a46cac01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4139","BK4009","VXRT","HHS"],"gpt_icon":0},{"id":"2531312730","title":"Ibio, Inc.盤中異動 快速上漲6.19%報1.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531312730","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531312730?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 21:33","pubTimestamp":1745933617,"startTime":"0","endTime":"0","summary":"北京时间2025年04月29日21时33分，Ibio, Inc.股票出现异动，股价急速上涨6.19%。截至发稿，该股报1.12美元/股，成交量12.66万股，换手率1.26%，振幅3.81%。Ibio, Inc.股票所在的生物技术行业中，整体跌幅为1.92%。Ibio, Inc.公司简介：iBio公司是一家临床前阶段生物技术公司，利用人工智能的力量开发精准抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429213337aa2c7e03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429213337aa2c7e03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","IBIO","BK4139"],"gpt_icon":0},{"id":"2531410753","title":"Corvus Pharmaceuticals, Inc.盤中異動 早盤股價大漲5.43%報3.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531410753","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531410753?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 21:32","pubTimestamp":1745933547,"startTime":"0","endTime":"0","summary":"北京时间2025年04月29日21时32分，Corvus Pharmaceuticals, Inc.股票出现异动，股价急速拉升5.43%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.55%。其相关个股中，Cyclacel Pharmaceuticals, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Tevogen Bio Holdings Inc C/Wts 14/02/2029 涨幅较大，Zyversa Therapeutics, Inc.、Onconetix, Inc.、Galmed Pharmaceuticals Ltd.较为活跃，换手率分别为132.52%、39.26%、11.58%，振幅较大的相关个股有Cyclacel Pharmaceuticals, Inc.、Ernexa Therapeutics Inc.、Promis Neurosciences Inc.，振幅分别为12.12%、12.10%、9.62%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家临床阶段的生物制药公司，致力于开发针对免疫系统关键细胞元素的药物和抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429213228aa2c7e00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429213228aa2c7e00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4568","CRVS"],"gpt_icon":0},{"id":"2531773684","title":"美國食品和藥物管理局局長稱解僱不會妨礙該局的藥物審查目標日期","url":"https://stock-news.laohu8.com/highlight/detail?id=2531773684","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531773684?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 20:42","pubTimestamp":1745930559,"startTime":"0","endTime":"0","summary":"美国食品和药物管理局局长表示，尽管特朗普政府大规模解雇了该机构的人员，但美国食品和药物管理局仍将实现完成新药审查的目标。路透 4 月初报道称，该机构大规模解雇 了 对新药审评 至关重要的   员工，包括所有负责管理新产品申请等记录的 员工。马卡里还表示，他可以在该机构独立做出决定。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4S3R71CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4588","BK4139","BK4568","BK4585"],"gpt_icon":1},{"id":"2531641786","title":"BUZZ-輝瑞公司季度利潤增長，維持 2025 年業績預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2531641786","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531641786?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 19:02","pubTimestamp":1745924560,"startTime":"0","endTime":"0","summary":"** 虽然第一季度营收不及预期，但仍坚持610-640亿美元的财年营收预期 ** 同时，维持 2.80 美元至 3.00 美元的财年每股收益预期。** 截至上次收盘，PFE 年累计下跌约 13 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4T3R7114:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002232.USD","LU0321505868.SGD","LU1023059063.AUD","PFE","BK4585","BK4534","LU1057294990.SGD","SG9999002224.SGD","BK4007","LU0058720904.USD","BK4581","LU0868494617.USD","LU0306807586.USD","SG9999011175.SGD","BK4568","LU1066051498.USD","LU0456855351.SGD","BK4533","SG9999003800.SGD","LU0321505439.SGD","BK4599","LU0122379950.USD","LU1894683348.USD","LU0225771236.USD","BK4550","LU0306806265.USD","BK4592","SG9999013999.USD","IE00BBT3K403.USD","SG9999001176.SGD","LU0289739699.SGD","LU1894683264.USD","LU0170899867.USD","LU1066053197.SGD","LU0985481810.HKD","SG9999001176.USD","IE00B19Z3B42.SGD","SGXZ57979304.SGD","IE00BLSP4239.USD","IE0002270589.USD","LU1883839398.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","LU0225284248.USD","LU0234572021.USD","BK4588","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2531785467","title":"輝瑞依靠削減成本抵消收入下降的影響","url":"https://stock-news.laohu8.com/highlight/detail?id=2531785467","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531785467?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 19:00","pubTimestamp":1745924425,"startTime":"0","endTime":"0","summary":"更新版 6-辉瑞依靠削减成本抵消收入下降的影响辉瑞公布喜忧参半的第一季度业绩，维持全年预期 COVID 疫苗销售好于预期，而抗病毒治疗销售下降预计到 2027 年底可节省 77 亿美元成本 第 8-9 段增加了首席执行官访谈中关于关税的评论Bhanvi Satija/Michael Erman. 路透4月29日 - 辉瑞PFE.N周二表示，公司将通过削减生产和研究业务的成本再节约17亿美元，尽管由于其COVID-19治疗药物Paxlovid的销售下降导致第一季度收入减少，但辉瑞仍强调了其运营效率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4T3R7108:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4588","LU0122379950.USD","LU1066053197.SGD","LU1066051498.USD","IE00BLSP4452.SGD","BK4568","LU1894683264.USD","LU0985481810.HKD","SGXZ57979304.SGD","BK4581","IE00BBT3K403.USD","LU1057294990.SGD","LU0225284248.USD","SG9999001176.USD","IE0002270589.USD","LU1883839398.USD","LU0225771236.USD","LU0868494617.USD","SG9999013999.USD","SG9999002224.SGD","LU0170899867.USD","BK4585","LU0234572021.USD","BK4533","LU0321505868.SGD","BK4550","SG9999011175.SGD","LU0306807586.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","PFE","LU1023059063.AUD","LU0058720904.USD","BK4592","LU0321505439.SGD","SG9999001176.SGD","IE000M9KFDE8.USD","LU0306806265.USD","LU0289739699.SGD","BK4007","BK4599","LU1894683348.USD","SG9999003800.SGD","SG9999002232.USD","LU0456855351.SGD","IE00B19Z3581.USD"],"gpt_icon":1},{"id":"2531378394","title":"輝瑞季度銷售額不及預期，COVID 治療收入下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2531378394","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531378394?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 18:49","pubTimestamp":1745923795,"startTime":"0","endTime":"0","summary":"辉瑞季度销售额不及预期，COVID 治疗收入下降路透4月29日 - 美国制药商辉瑞PFE.N周二公布的第一季度收入低于华尔街预期，受其COVID抗病毒治疗药物Paxlovid销售下滑的影响。 LSEG的数据显示，该公司第一季度总营收为137.0亿美元，而分析师预期为139.1亿美元。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4S3R70Z5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4592","IE00BBT3K403.USD","LU0170899867.USD","LU0058720904.USD","BK4588","LU0868494617.USD","LU0306806265.USD","BK4581","BK4568","LU1894683264.USD","IE00B19Z3B42.SGD","LU0122379950.USD","BK4599","LU0321505868.SGD","IE00B19Z3581.USD","LU0289739699.SGD","LU0225284248.USD","IE00BLSP4452.SGD","SG9999002224.SGD","BK4533","LU0306807586.USD","BK4585","IE00BLSP4239.USD","LU1883839398.USD","LU1057294990.SGD","LU0234572021.USD","LU0985481810.HKD","LU1066053197.SGD","LU1023059063.AUD","SG9999003800.SGD","SG9999011175.SGD","IE000M9KFDE8.USD","IE0002270589.USD","SG9999013999.USD","BK4534","SG9999002232.USD","LU0321505439.SGD","BK4007","LU0225771236.USD","PFE","SG9999001176.USD","LU0456855351.SGD","SG9999001176.SGD","BK4550","SGXZ57979304.SGD","LU1894683348.USD","LU1066051498.USD"],"gpt_icon":0},{"id":"2531022292","title":"阿斯利康一季報：中國區收入18億美元，ADC藥物驅動新增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2531022292","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531022292?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 17:56","pubTimestamp":1745920574,"startTime":"0","endTime":"0","summary":"根据财报，今年一季度阿斯利康在美国收入 56.46 亿美元，同比增长10%，占总营收的 42%；中国区收入 18.05 亿美元，同比增长5%，占总营收的 13%。而ADC 药物德曲妥珠单抗增长势头强劲，今年第一季度的销售额为10.86 亿美元。阿斯利康的财报印证了其在“专利悬崖”前的未雨绸缪：通过ADC药物打开新增量，以多元化管线平衡风险，并借力中国市场实现全球化纵深。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504291758349749f61d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504291758349749f61d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","ADC","BK4231","LU1829250122.USD","AZN","LU2236285917.USD","BK4585","LU2462157665.USD","BK4588","LU0320765992.SGD","LU2456880835.USD","LU0889565916.HKD","BK4080","LU0109394709.USD","LU2417539215.USD","BK4007"],"gpt_icon":0},{"id":"2531270717","title":"阿斯利康盤前挫2.65% 將終止針對其前列腺癌治療藥物三期臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2531270717","media":"金吾资讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531270717?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 17:00","pubTimestamp":1745917203,"startTime":"0","endTime":"0","summary":"金吾财讯 | 阿斯利康(AZN)盘前股价下挫，暂跌2.65%，报68.08美元。消息面上，公司将终止针对其前列腺癌治疗药物Truqap的CAPITello-280三期临床试验，原因是该试验不太可能达到双重主要终点。公司周二称，这一决定是在审查了独立数据监测委员会建议的中期分析数据后作出的。该公司表示，与使用多西他赛和雄激素剥夺疗法（ADT）加安慰剂的对照组相比，Truqap联合多西他赛和ADT的治疗方案，在转移性去势抵抗性前列腺癌患者中，可能无法达到影像学无进展生存期和总生存期的主要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504291701509749e2b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504291701509749e2b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","LU1829250122.USD","LU2462157665.USD","BK4588","LU2236285917.USD","LU0889565916.HKD","LU0320765992.SGD","LU2417539215.USD","AZN","BK4007","LU2456880835.USD","LU0109394709.USD","BK4585"],"gpt_icon":0},{"id":"2531475201","title":"美股異動丨阿斯利康盤前跌超3% 首季收入遜預期 或因未支付進口稅面臨中國罰款","url":"https://stock-news.laohu8.com/highlight/detail?id=2531475201","media":"格隆汇APP","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531475201?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 16:51","pubTimestamp":1745916660,"startTime":"0","endTime":"0","summary":"阿斯利康(AZN.US)盘前跌超3%，报67.81美元。消息面上，阿斯利康第一季度总营收135.9亿美元，同比增长10%，低于市场预期的138亿美元；核心每股收益2.49美元，同比增长21%。另外，由于涉嫌在中国未缴纳进口税，该公司已收到深圳市有关部门的意见，认为疑似未支付的金额约为160万美元，如果被认定负有责任，可能会被处以一至五倍的罚款。(格隆汇)\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2025-04-29/doc-ineuvnxv5672354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0320765992.SGD","BK4007","LU2462157665.USD","LU1829250122.USD","LU2236285917.USD","LU2456880835.USD","BK4568","BK4585","BK4588","LU0889565916.HKD","LU2417539215.USD","AZN","LU0109394709.USD"],"gpt_icon":0},{"id":"2531211672","title":"阿斯利康(AZN.O)CEO：美國關税對阿斯利康的影響將是短暫的。","url":"https://stock-news.laohu8.com/highlight/detail?id=2531211672","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531211672?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 14:51","pubTimestamp":1745909467,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4585","LU0889565916.HKD","BK4568","AZN","LU2417539215.USD","LU2456880835.USD","LU2462157665.USD","LU2236285917.USD","LU0320765992.SGD","BK4007","LU1829250122.USD","BK4588","LU0109394709.USD"],"gpt_icon":0},{"id":"2531224997","title":"阿斯利康 Q1：中國區收入 18 億美元，Enhertu 大賣 10.86 億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531224997","media":"Insight数据库","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531224997?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 14:25","pubTimestamp":1745907932,"startTime":"0","endTime":"0","summary":"4 月 29 日，阿斯利康发布 2025 年一季度财报，营收 135.88 亿美元，同比增长 10%，其中产品收入销售 128.75 亿美元（+9%）。来源：阿斯利康 2025 Q1 财报，下同从地区来看，美国收入 56.46 亿美元，占总营收的 42%；中国是阿斯利康继美国、欧洲后的第三大市场，今年 Q1 收入 18.05 亿美元（+5%），占总营收的 13%。ADC 方面，德曲妥珠单抗是第一三共和阿斯利康携手打造的第一款 ADC，自 2019 年 12 月上市以来，短短 5 年时间，24 年销售额便已突破 34 亿美元，25 年有望超过 40 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429150336a6ccca72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429150336a6ccca72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","BK4007","LU2462157665.USD","LU1829250122.USD","LU2236285917.USD","LU2456880835.USD","BK4568","BK4585","BK4588","LU0889565916.HKD","LU2417539215.USD","AZN","LU0109394709.USD"],"gpt_icon":0},{"id":"2531021943","title":"強生4月28日成交額為9.02億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531021943","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531021943?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 09:47","pubTimestamp":1745891240,"startTime":"0","endTime":"0","summary":"美东时间2025年4月28日，强生成交额为9.02亿美元，成交额较昨日减少32.23%，当日成交量为581.52万股。强生于2025年4月28日涨0.5%，报155.35美元，该股过去5个交易日跌1.0%，年初至今涨8.27%，过去60日涨2.43%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-28|9.02亿|-32.23%|581.52万|#|2025-04-25|13.31亿|3.66%|864.39万|#|2025-04-24|12.84亿|-9.23%|831.04万|#|2025-04-23|14.15亿|25.78%|909.94万|#|2025-04-22|11.25亿|14.06%|713.63万|强生公司是世界上最大的、最多元化的医疗保健公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429094728a6cc7873&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429094728a6cc7873&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0345769128.USD","LU1059921491.USD","LU2505996681.GBP","IE00BSNM7G36.USD","BK4533","LU1061106388.HKD","IE0002141913.USD","IE00B19Z3581.USD","SG9999002232.USD","LU0122379950.USD","BK4581","BK4568","LU1585245621.USD","LU2089984988.USD","SG9999002224.SGD","IE00BFTCPJ56.SGD","JNJ","LU1732799900.SGD","IE0034235303.USD","LU2129689514.USD","IE00BLSP4452.SGD","LU1066051811.HKD","BK4550","LU0882574055.USD","BK4534","LU2468319806.SGD","LU1280957306.USD","LU1261432733.SGD","IE00B3T34201.USD","LU0640476718.USD","LU1066051498.USD","LU2347655156.SGD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","IE00BDGV0183.EUR","LU0345770308.USD","LU1221951129.SGD","LU1674673428.USD","LU1162221912.USD","LU1894683348.USD","IE00BJJMRZ35.SGD","LU0114720955.EUR","LU2129689431.USD","LU2133065610.SGD","IE000M9KFDE8.USD","LU0098860793.USD","LU1506573853.SGD","LU2505996509.AUD","SG9999001440.SGD","BK4585"],"gpt_icon":0},{"id":"2531151752","title":"吉利德科學4月28日成交額為9.98億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531151752","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531151752?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 09:35","pubTimestamp":1745890518,"startTime":"0","endTime":"0","summary":"美东时间2025年4月28日，吉利德科学成交额为9.98亿美元，成交额较昨日减少31.77%，当日成交量为945.89万股。吉利德科学于2025年4月28日涨3.07%，报106.34美元，该股过去5个交易日涨1.93%，年初至今涨15.94%，过去60日涨10.46%。吉利德对Pharmasset的收购带来了丙型肝炎药物索磷布韦片的使用权，该药物也是仍为治疗标准的较新的联合方案的一部分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429093523a6cc72cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429093523a6cc72cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4578","BK4532","BK4583","IE00B19Z3581.USD","LU2087621335.USD","IE00B3T34201.USD","LU0058720904.USD","BK4139","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","LU1571399168.USD","BK4588","BK4550","LU0289739699.SGD","LU2468319806.SGD","LU0109394709.USD","BK4566","BK4585","IE00B7SZLL34.SGD","IE0002270589.USD","GILD","LU0889565916.HKD","LU0234570918.USD","LU2089984988.USD","LU1430594728.SGD","BK4568","LU1839511570.USD","LU1066053197.SGD","LU0320765992.SGD","LU1585245621.USD","LU1066051498.USD","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2531218448","title":"Virtual Protocol生態代幣普漲，GAME 24H漲幅超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531218448","media":"Odaily","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531218448?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 09:17","pubTimestamp":1745889468,"startTime":"0","endTime":"0","summary":"Odaily星球日报讯 GMGN 行情数据显示，Virtual Protocol 生态代币今日普涨，其中：\nVIRTUAL 市值现报 9.6 亿美元，24 小时涨幅 41.1%；\naixbt by Virtuals（AIXBT）市值现报 1.3 亿美元，24 小时涨幅 21.5%；\nGAME by Virtuals（GAME）市值现报 6600 万美元，24 小时涨幅 51.4%；\nVaderAI by Virtuals（VADER）市值报 3700 万美元，24 小时涨幅 51.9%；\nLuna by Virtuals（LUNA）市值现报 2300 万美元，24 小时涨幅 44.2%。\n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.odaily.news/newsflash/428849?source=share","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"odaily_live","symbols":["BK4585","BK4572","NA","LU0738911758.USD","LU","LU0949170772.SGD","IE0034390439.USD","BK4139","IE00B19Z6F94.USD","BK4535","BK4104","TU","BK4504","BK4141","BK4566","BK4115","BK4077","LU0661504455.SGD","BK4166","BK4526","BK4085","LU1046422090.SGD","VIR","GAME","BK4108","BK4568","AL","BK4588"],"gpt_icon":0},{"id":"2531594213","title":"阿斯利康4月28日成交額為5.63億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531594213","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531594213?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 09:16","pubTimestamp":1745889415,"startTime":"0","endTime":"0","summary":"美东时间2025年4月28日，阿斯利康成交额为5.63亿美元，成交额较昨日增加21.81%，当日成交量为802.34万股。阿斯利康于2025年4月28日涨0.52%，报69.93美元，该股过去5个交易日涨4.53%，年初至今涨8.47%，过去60日跌0.37%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-28|5.63亿|21.81%|802.34万|#|2025-04-25|4.62亿|94.02%|666.27万|#|2025-04-24|2.38亿|-38.92%|343.21万|#|2025-04-23|3.90亿|-1.09%|567.40万|#|2025-04-22|3.94亿|128.16%|580.70万|1999 年，瑞典阿斯特拉公司与英国捷利康集团合并，成立了阿斯利康公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429091704a6cc6d0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429091704a6cc6d0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU0109394709.USD","LU0320765992.SGD","LU2456880835.USD","LU2462157665.USD","LU2236285917.USD","LU0889565916.HKD","LU2417539215.USD","BK4585","BK4568","LU1829250122.USD","BK4007","AZN"],"gpt_icon":0},{"id":"2531829517","title":"敬告客戶-以下稿子現予以撤銷-特朗普吹捧Nvidia、J&J、現代、豐田在美投資","url":"https://stock-news.laohu8.com/highlight/detail?id=2531829517","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531829517?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 07:08","pubTimestamp":1745881693,"startTime":"0","endTime":"0","summary":"敬告客户-以下稿子现予以撤销-特朗普吹捧Nvidia、J&J、现代、丰田在美投资STORY_NUMBER: L4T3R623MSTORY_DATE: 28/04/2025STORY_TIME: 2308 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nL4T3R623M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","LU2471134796.USD","LU2168564222.USD","BK4587","LU0820561818.USD","3NVD.UK","LU1868837136.USD","BK4567","NVD","LU1066053197.SGD","SG9999001176.SGD","LU0494093205.USD","LU2750360641.GBP","LU0689626769.HKD","IE00BYXW3230.USD","LU1037948897.HKD","NVDX","LU2471134523.USD","NVD2.UK","NVDS.UK","ORCL","LU0234572021.USD","NVIW.SI","GM","NVDA","LU0345770308.USD","GE","SNVD.UK","LU0276348264.USD","NVD3.UK","2NVD.UK","LU0786609619.USD","NVDS","LU1035775433.USD","LU0106261372.USD","LU0957808578.USD","JNJ","BK4559","NVDD","BK4579","SG9999015358.SGD","LU0882574055.USD","BK4585","NVDY","LU2413666426.HKD","LU0234570918.USD","LU2168564149.EUR","NVDU"],"gpt_icon":1},{"id":"2531646022","title":"吉利德科學盤中異動 股價大漲3.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531646022","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531646022?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 03:27","pubTimestamp":1745868465,"startTime":"0","endTime":"0","summary":"北京时间2025年04月29日03时27分，吉利德科学股票出现异动，股价快速拉升3.00%。吉利德科学股票所在的制药行业中，整体涨幅为0.24%。吉利德科学公司简介：吉利德科学开发和营销用于治疗威胁生命的传染病的疗法，其投资组合的核心集中在艾滋病毒，乙型和丙型肝炎。消息层面，截至03时27分，《大摩：维持Gilead Sciences评级，由增持调整至增持评级, 目标价由130.00美元调整至135.00美元。》资讯为影响吉利德科学的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042903274594e64b2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042903274594e64b2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B19Z3581.USD","LU1571399168.USD","IE00BKVL7J92.USD","BK4585","LU1430594728.SGD","BK4568","LU0058720904.USD","BK4550","IE00B19Z3B42.SGD","LU1066053197.SGD","GILD","LU1066051498.USD","IE00BSNM7G36.USD","BK4532","LU0234570918.USD","LU1839511570.USD","IE00B3T34201.USD","BK4583","BK4566","LU2087621335.USD","LU1585245621.USD","IE0002270589.USD","LU0109394709.USD","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4139","LU2089984988.USD","LU2468319806.SGD","IE00B7SZLL34.SGD","LU0289739699.SGD","BK4578","LU0889565916.HKD","BK4588"],"gpt_icon":0},{"id":"2531234854","title":"Nanoviricides, Inc.盤中異動 快速下挫7.04%報1.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531234854","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531234854?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 23:43","pubTimestamp":1745855016,"startTime":"0","endTime":"0","summary":"北京时间2025年04月28日23时43分，Nanoviricides, Inc.股票出现波动，股价大幅跳水7.04%。Nanoviricides, Inc.股票所在的生物技术行业中，整体涨幅为0.57%。其相关个股中，Cg Oncology, Inc.、Regulus Therapeutics Inc.、Portage Biotech Inc.涨幅较大，Galmed Pharmaceuticals Ltd.、Portage Biotech Inc.、Springworks Therapeutics, Inc.较为活跃，换手率分别为2446.33%、470.49%、84.30%，振幅较大的相关个股有Galmed Pharmaceuticals Ltd.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Regulus Therapeutics Inc.，振幅分别为53.50%、36.31%、33.79%。Nanoviricides, Inc.公司简介：Nanoviricides Inc是一家纳米生物制药公司，致力于发现、开发和商业化治疗剂，以推进对患有危及生命的病毒感染患者的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428234336a46ab160&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428234336a46ab160&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NNVC","BK4568","BK4139"],"gpt_icon":0},{"id":"2530233536","title":"BUZZ-Insulet 任命新任首席執行官，預示利潤前景改善，公司股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2530233536","media":"路透中文","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530233536?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 23:00","pubTimestamp":1745852405,"startTime":"0","endTime":"0","summary":"4月28日 - ** 医疗设备制造商 Insulet 宣布更换首席执行官，并对 2025 年的利润前景持乐观态度，该公司PODD.O股价周一上涨 1%，至 263.34 美元。** 公司定于 5 月 8 日收盘后发布第一季度财报。鉴于首席执行官的交接，该公司推迟了之前计划的 6 月 5 日投资者日活动，并打算重新安排。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nL4S3R61GO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU0234570918.USD","LU1718418525.SGD","IE00B3PB1722.GBP","BK4504","LU1084165304.USD","LU0345769631.USD","IE00BFTCPJ56.SGD","IE00BLSP4452.SGD","LU1066053197.SGD","IE00BVYPNW00.USD","LU1430594728.SGD","IE00BJT1NW94.SGD","LU0345769128.USD","LU2129689605.HKD","BK4585","LU0098860793.USD","LU1196500208.SGD","LU0882574055.USD","IE00B4R5TH58.HKD","IE00B42XCP33.USD","LU0345770993.USD","JNJ","IE00BGHQF631.EUR","BK4082","LU1162221912.USD","LU1585245621.USD","IE00B19Z3581.USD","IE0002141913.USD","LU0889566641.SGD","IE00B1BXHZ80.USD","BK4559","PODD","IE00B2B36J28.USD","LU1267930813.SGD","LU0289739699.SGD","LU1221951129.SGD","LU1929549753.HKD","LU2505996509.AUD","LU1935042991.SGD","LU0912757837.SGD","BK4551","BK4592","LU2592432038.USD","LU1244550494.USD","IE00B19Z3B42.SGD","IE00BN8TJ469.HKD","BK4568","LU1023059063.AUD","LU1244550221.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":191,"code":"91000000","status":"200"}]}}